{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:37:51Z","timestamp":1775554671803,"version":"3.50.1"},"reference-count":21,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T00:00:00Z","timestamp":1545350400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCT00117975"],"award-info":[{"award-number":["NCT00117975"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCT00553501"],"award-info":[{"award-number":["NCT00553501"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCT01145495"],"award-info":[{"award-number":["NCT01145495"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCI K24CA201524"],"award-info":[{"award-number":["NCI K24CA201524"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Follicular lymphoma (FL) patients treated with firstline R\u2010CHOP who experience progression of disease (POD) within 2\u00a0years have a shorter survival than those who do not have POD within 2\u00a0years. Whether this observation holds for patients treated initially with biologic immunotherapy alone is unknown. We performed a retrospective analysis of 174 patients pooled from three frontline rituximab (R)\u2010based nonchemotherapy doublet trials: R\u2010galiximab (Anti\u2010CD80, CALGB 50402), R\u2010epratuzumab (Anti\u2010CD22, CALGB 50701), and R\u2010lenalidomide (CALGB 50803) to determine outcomes of early progressors and risk factors for early POD, defined as progression within 24\u00a0months from study entry. Twenty\u2010eight percent (48\/174) of patients had early POD. After adjusting for the Follicular Lymphoma International Prognostic Index (FLIPI), patients with early POD from study entry had a worse OS compared with patients who did not progress within 2\u00a0years (HR\u00a0=\u00a04.33 (95% CI 1.50\u201012.5), <jats:italic>P<\/jats:italic>\u00a0=\u00a00.007). For early POD, the 2\u2010year survival was 80% vs 99% for nonearly POD, and the 5\u2010year survival was 74% vs 90%, respectively. These findings suggest that the adverse survival of patients with early POD may be independent of initial treatment modality.<\/jats:p>","DOI":"10.1002\/cam4.1918","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T15:38:44Z","timestamp":1545406724000},"page":"165-173","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6027-3359","authenticated-orcid":false,"given":"Frederick","family":"Lansigan","sequence":"first","affiliation":[{"name":"Dartmouth College Norris Cotton Cancer Center Lebanon New Hampshire"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Barak","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center Duke University Durham North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandelyn","family":"Pitcher","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center Duke University Durham North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sin\u2010Ho","family":"Jung","sequence":"additional","affiliation":[{"name":"Alliance Statistics and Data Center Duke University Durham North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[{"name":"MedStar Georgetown University Hospital Washington District of Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myron","family":"Czuczman","sequence":"additional","affiliation":[{"name":"Celgene, Inc. Morristown New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Martin","sequence":"additional","affiliation":[{"name":"Weill Medical College of Cornell University New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Hsi","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation Cleveland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiko","family":"Sch\u00f6der","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Smith","sequence":"additional","affiliation":[{"name":"Alliance Protocol Office University of Chicago Chicago Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine St. Louis Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"Weill Medical College of Cornell University New York New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4229-2569","authenticated-orcid":false,"given":"Kristie A.","family":"Blum","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine Atlanta Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,12,21]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-006-0036-3"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.3991"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00169-2"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-717355"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24492"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.5853"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.4786"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70027-0"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr620"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28299"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.32.15_suppl.8521"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"e_1_2_7_15_1","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.V126.23.334.334","article-title":"Interfollicular CD10 expression and follicular PD1 Tumor\u2010infiltrating lymphocytes as biologic risk factors in patients with previously untreated follicular lymphoma receiving rituximab\u2010based biologic therapy: an alliance correlative science study (CALGB 50901, 50402, 50701, 50803, 50401)","volume":"126","author":"Sohani AR","year":"2015","journal-title":"Blood"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24401"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-014-1576-0"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13332"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181e9343d"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2017.03.023"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.030320"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14448"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.1918","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.1918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T11:37:32Z","timestamp":1694691452000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.1918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,21]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1002\/cam4.1918"],"URL":"https:\/\/doi.org\/10.1002\/cam4.1918","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,21]]},"assertion":[{"value":"2018-06-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}